Eleonora Teplinsky, MD, FASCO

Deep dive on my recent Substack all about oligometastatic breast cancer- what oligometastatic BC is, what patients need to know and new data! open.substack.com/pub/drteplinsk…

@fumikochino @ASCO Soo late but glad you made it! See you soon!!

@drteplinsky @ASCO I lost count of the number of delays and gate changes. 😵‍💫 but finally arrived. 🥱

Canceled/delayed flights ✈️…🚊to DC for @ASCO Cancer Communications Committee meeting! One of my favorite meetings of the year!

Who's going to pay for daycare? You're asking us to come during the daytime when a lot of us work. Is it close to a bus line? 🚨@oncoalert: New podcast on diversity in cancer #clinicaltrials w/ bioethics expert Dr Miller & pt #Advocate @warriormegsie. 🎙️ ascopubs.org/do/diversity-c…

Overall survival is not the correct endpoint for a screening study which is what some people want. We want to try to prevent unnecessary suffering in our patients: seizures, midline shift, reduce WBRT rates and improve QOL. Seems like a “no brainer” (pun intended).

@fumikochino @ASCO Oh no!! Good luck!! 🤞

@drteplinsky @ASCO Hope I will see you there! My flight has already been moved twice 🤞🤞🤞🫠

@OncBrothers @JaniceTNBCmets @AMJohnston1315 @OncUpdates @OncoAlert @SusanGKomen I do order upfront and generally do surveillance imaging annually especially in TNBC and HER2 disease. Guidelines on this vary but I have picked up a lot of asymptomatic disease.

No clear consensus and practices differ but more and more data is supporting that we should get CNS imaging upfront for metastatic breast cancer! #OncTwitter #bcsm @JaniceTNBCmets @AMJohnston1315 @OncUpdates @OncoAlert @SusanGKomen

Master CDK4/6i therapies HR+, HER2- #BreastCancer with expert guidance from Drs. Hurvitz, Hussein, Barrios, and Teplinsky (@drteplinsky) in this new PeerView #MedEd activity, presented in partnership with @LivingBeyondBC! bit.ly/4fTcncI #Oncology

In mBC, not all imaging changes mean your therapy has stopped working and switching too early is a real risk. 1/ RECIST 1.1 sets a clear bar for progression: ≥20% increase in the sum of target lesion diameters (with ≥5mm absolute increase), unequivocal progression of non-target lesions, or new lesions. Not every change on imaging meets this threshold. 2/ Three scenarios commonly and incorrectly flagged as progression: new asymptomatic sclerotic bone lesions, small mm asymptomatic changes in known lesions, and increased SUV on PET without corresponding size change. None of these, in isolation, trigger a therapy switch for me. 3/ Sclerotic bone lesions deserve particular attention. When effective therapy kills tumor cells in bone, the body lays down new bone matrix appearing dense and white on CT. This is a healing response, not new disease. 4/ The consequences of switching too early are real: loss of disease control from a working regimen, premature exhaustion of sequencing options. 5/ My approach: I integrate clinical symptoms, tumor markers, and serial scans together before making any decision to change therapy. 6/ Bottom line: confirm true progression before changing course. When in doubt, a short interval rescan is almost always preferable to an unnecessary switch. #BreastCancer #MedOnc

🚶‍♀️🏋️‍♂️ #Exercise may reduce #cancer-related cognitive impairment among people starting #chemotherapy. Clinicians should tell patients “to avoid inactivity at all costs,” Dr. Karen M. Mustian @UR_Med @URochesterSurg @WilmotCancer tells @GoHealio. vist.ly/4unju

Could GLP1 drugs ⬆️ survival in pts with brain mets? In real world data: -⬇️ all cause mortality from date of brain met dx -limitations: cause of death (cancer related or not) unknown -? mediated by reduced neuroinflammation or other factors? jamanetwork.com/journals/jaman…

@YLeyfman Congrats!!

Honored to be included in this outstanding group of innovators. It is especially meaningful to be recognized alongside colleagues and mentors who have helped shape the next generation of oncology.

Another day, another sensational and click-bait headline from @nypost. The actual study is here: jamanetwork.com/journals/jaman…. I break down the study in this video ⬇️ and in my Substack: open.substack.com/pub/drteplinsk….

“The Estrogen Myth: What Survivors Deserve to Know” Episode: youtu.be/2TfMrRcmGeQ?si… This week on @Perftwisted with @NicoleEggert we’re tackling one of the most misunderstood topics in survivorship: estrogen. Are topical estrogen products actually safe after breast cancer? And more importantly, should you be using them? We’re joined by Dr. Elenora Teplinsky, a medical breast and gynecologic oncologist, who breaks down the science behind treating menopause symptoms after cancer treatment, why vaginal health matters, and how quality of life is not a luxury, it’s part of survivorship. And of course we have another great segment of #nicolesmailbag #breastcancer #estrogen #menopause

New data from the SONIA trial shows no overall survival benefit to using CDK4/6 inhibitors in the first line versus second line for advanced breast cancer. Does this change your sequence strategy? @JAMAOnc @OncoAlert @BreastCancerNow #breastcancer

Drs. Hurvitz, Hussein, Barrios, and Teplinsky (@drteplinsky) dive into the latest data on CDK4/6i for HR+, HER2- #BreastCancer in this new PeerView #MedEd activity, presented in partnership with @LivingBeyondBC. Watch now! bit.ly/4fTcncI #Oncology

Beyond thrilled to share my book (!!!) Beyond The Pink: Navigating Life, Health and Breast Cancer is available for pre-order!! It will be released by @gcpbalance @HachetteUS on September 29, 2026.  This book is for anyone affected by breast cancer in any way: whether you have been newly diagnosed, are a survivor, living with breast cancer, are a previvor, or are a family member or friend wanting to learn more. It has been such an honor to write this book and I can’t wait to share it!! gcp-balance.com/titles/dr-eleo…

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma buff.ly/Rx83psF On February 10, 2026, the FDA approved pembrolizumab (Keytruda), alone or with berahyaluronidase alfa-pmph (Keytruda Qlex), plus paclitaxel, with or without bevacizumab, for adults with PD-L1–positive (CPS≥1) platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after one or two prior therapies. In the KEYNOTE-B96 trial, the regimen improved progression-free and overall survival versus placebo. The PD-L1 IHC 22C3 pharmDx was also approved as a companion diagnostic. #OvarianCancer Pinging Friends and Faculty @European Society of Gynaecological Oncology @Ane Gerda Zahl Eriksson @womenofteal @EngageEsgo #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago @ESGO_society

We are excited to announce that the Valley-Mount Sinai Hematology/Oncology Fellowship Program in Paramus, NJ is officially accredited by the ACGME. We will welcome our first class of fellows in July 2027! @drteplinsky @ValleyHealthNJ #hemeoncfellowship

Pembrolizumab + paclitaxel (+/- bev) now @US_FDA ✅ for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma w/ PD-L1 CPS≥1 based off #KNB96: - mPFS 8.3 vs. 7.2mos (HR: 0.72) - mOS 18.2 vs. 14mos (HR: 0.79) #gynsm #OncTwitter #MedTwitter